drugset / Trial / NCT04963283
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
Phase 2
Active not recruiting
48 enrolled
University of Colorado, Denver
Bristol-Myers Squibb · collabCriterium, Inc. · collabExelixis · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
Data from a prior phase II study of single agent cabozantinib in metastatic, refractory colorectal cancer (NCT03542877) combined with the compelling preclinical data in colorectal mouse models utilizing cabozantinib combined with nivolumab have led to this concept for a clinical trial to combine cabozantinib and nivolumab in patients with metastatic MSS CRC in the third line setting and beyond.
Timeline
- Start
- 2021-06-23
- Primary completion
- 2026-02-24
- Completion
- 2027-02-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabozantinib | Small molecule | 40 mg | Oral |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |